Related references
Note: Only part of the references are listed.Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
Isabel Heidegger et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2013)
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer
Robert W. Ross et al.
CANCER (2012)
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
Shintaro Narita et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Telomere and Microtubule Targeting in Treatment-Sensitive and Treatment-Resistant Human Prostate Cancer Cells
Bin Zhang et al.
MOLECULAR PHARMACOLOGY (2012)
Gemcitabine and Docetaxel in Metastatic, Castrate-Resistant Prostate Cancer Results From a Phase 2 Trial
Jorge A. Garcia et al.
CANCER (2011)
Modulation of P-gp expression by lapatinib
Grainne Dunne et al.
INVESTIGATIONAL NEW DRUGS (2011)
Toluidinesulfonamide Hypoxia-Induced Factor 1 Inhibitors: Alleviating Drug-Drug Interactions through Use of PubChem Data and Comparative Molecular Field Analysis Guided Synthesis
Bernd Wendt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Before Radical Prostatectomy in High Risk Patients
Paul R. Womble et al.
JOURNAL OF UROLOGY (2011)
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
Amanda J. O'Neill et al.
MOLECULAR CANCER (2011)
Drug resistance in metastatic castration-resistant prostate cancer
Bostjan Seruga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Guidelines for the welfare and use of animals in cancer research
P. Workman et al.
BRITISH JOURNAL OF CANCER (2010)
Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer
Neeraj Agarwal et al.
FUTURE ONCOLOGY (2010)
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines
D. M. Collins et al.
INVESTIGATIONAL NEW DRUGS (2010)
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2009)
Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line
Joanne Keenan et al.
PROTEOMICS (2009)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer
Nobuyuki Kikuno et al.
EUROPEAN UROLOGY (2007)
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jeffrey R. Jackson et al.
NATURE REVIEWS CANCER (2007)
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer
Jean-Marc Ferrero et al.
CANCER (2006)
Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma
William Tester et al.
CANCER JOURNAL (2006)
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai et al.
NATURE PROTOCOLS (2006)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma - Cancer and leukemia group B 99813
WK Oh et al.
CANCER (2003)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
Share Paper
